Cascade Biocatalysts Inc.
Denver, CO
- UEI
- CTFCBZCWLE81
- CAGE
- 9FQZ6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3960 Niagara St b, Denver, CO 80207, USA
- Website
- cascadebio.com
- Founded
- 1992
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Materials
- Chemicals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of California Irvine | 2452698 | $529,229 | |
| University Of California Irvine | 2452698 | $722,553 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Roke Biotechnologies LLC | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Invizyne Technologies Inc. | Monrovia, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Partillion Bioscience Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Owic Technologies Inc. | Ithaca, NY | — |
| Arzeda Corp | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Cascade Biocatalysts Inc., a Denver-based for-profit manufacturer of biocatalytic systems, operates as a federal grant recipient focused on enzyme immobilization and cofactor regeneration technology for pharmaceutical and specialty chemical manufacturing. The company is not a federal contract prime or contractor vehicle awardee; its federal footprint consists entirely of R&D grant awards from the National Science Foundation and the National Institutes of Health, with two sub-award positions under University of California Irvine prime grants.
Cascade's core capability centers on enzyme stabilization through engineered polymer-brush immobilization techniques and cofactor regeneration systems designed to extend enzyme lifespan, reduce manufacturing costs, and accelerate adoption of biocatalysis in pharmaceutical active pharmaceutical ingredient synthesis and specialty chemical production. The company has received three prime grants totaling $1.832 million since December 2023: a $274,918 NSF SBIR Phase I grant (CFDA 47.084, awarded December 15, 2023, completed May 31, 2024) for demonstration of polymer-enzyme interaction scaling in enzyme stabilization; a $1.25 million NSF Technology, Innovation, and Partnerships cooperative agreement (CFDA 47.084, awarded September 1, 2025, completing August 31, 2027) for Phase II SBIR work on manufacturing scale-up to 100-kilogram batch sizes and unit cost reduction through process intensification; and a $306,871 National Center for Advancing Translational Sciences project grant (CFDA 93.350, awarded August 15, 2026, completing August 14, 2027) for immobilized cofactor-regeneration resin design and evaluation in representative pharmaceutical reactions. Cascade also holds two sub-award positions under University of California Irvine prime grants, performing process development engineering and analytical work on chiral molecule scale-up and purification optimization for complex coacervate colloid systems (sub-awards dated August 6, 2025, and May 11, 2026).
Customer concentration is split between the National Science Foundation (four awards) and the Department of Health and Human Services National Institutes of Health (one award). Two awards reach ultimate completion within the next twenty-four months. The vendor's federal footprint reflects early-stage SBIR investment in biomanufacturing infrastructure rather than production contracting or supply relationships.
Quick answers
Is Cascade Biocatalysts Inc. registered in SAM.gov?
Yes. Cascade Biocatalysts Inc.'s SAM.gov registration is active through July 29, 2027.
What is Cascade Biocatalysts Inc.'s most recent federal award?
Cascade Biocatalysts Inc.'s most recent federal grant award is Immobilized cofactor regeneration systems to accelerate enzymatic API manufacturing - title: immobilized cofactor… (R43TR006332), from National Center for Advancing Translational Sciences (NIH), on August 15, 2026.
On GovTribe
See Cascade Biocatalysts Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors